Pharmacokinetic drug evaluation of albutrepenonacog alfa (CSL654) for the treatment of hemophilia

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 11, 2016, Pages 1359-1365

  Morfini, Massimo ^a  

^a Italian Association of Haemophilia Centres AICE   (Italy)

Author keywords

Albumin; albutrepenonacog alfa; clearance; CSL 654; extravascular distribution; half Life; immunogenicity; PD; PK; rIX FP

Indexed keywords

BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ANAPHYLAXIS; ARTICLE; BIOENGINEERING; BLOOD CLOTTING; CHO CELL LINE; CYANOSIS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPNEA; HEMOPHILIA; HUMAN; MARKET; NEPHROSIS; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PROTEINURIA; SHOCK; SUBSTITUTION THERAPY; VOLUME OF DISTRIBUTION;

EID: 84989837111     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1080/17425255.2016.1240168     Document Type: Article

References (56)

1. L.A.Valentino, L.Rusen, I.Elezovic, et al. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia. 2014;20:398–406.
2. V.S.Blanchette, M.Manco-Johnson, E.Santagostino, et al. Optimizing factor prophylaxis for the haemophilia population:where do we stand?. Haemophilia. 2004;10(Suppl 4):97–104. Review.
3. B.Brand, S.Dunn, R.Kulkarni Challenges in the management of haemophilia on transition from adolescence to adulthood. Eur J Haematol. 2015;95(Suppl 81):30–35. Review.
4. P.Giangrande. The future of hemophilia treatment:longer-acting factor concentrates versus gene therapy. Semin Thromb Hemost. 2016;42:513–517.
5. D.DiMichele. Inhibitor development in haemophilia B:an orphan disease in need of attention. Br J Haematol. Aug 2007 ;138(3):305–315. Review
6. Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products (Draft). [cited 2016 September 26] Available from:www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/06/WC500187409.pdf
7. S.Schulte. Half-life extension through albumin fusion technologies. Thromb Res. 2009;124(Suppl 2):S6–S8.
8. H.J.Metzner, T.Weimer, U.Kronthaler, et al. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost. 2009;102:634–644.
9. M.W.Nolte, T.C.Nichols, J.Mueller-Cohrs, et al. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs. J Thromb Haemost. 2012;10:1591–1599.
10. B.L.Osborn, L.Sekut, M.Corcoran, et al. Albutropin:a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol. 2002;456:149–158.
11. B.L.Osborn, H.S.Olsen, B.Nardelli, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther. 2002;303:540–548.
12. W.Wang, Y.Ou, Y.Shi. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm Res. 2004;21:2105–2111.
13. A.Duttaroy, P.Kanakaraj, B.L.Osborn, et al. Development of a long-acting insulin analog using albumin fusion technology. Diabetes. 2005;54:251–258.
14. J.E.Matthews, M.W.Stewart, E.H.De Boever, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:4810–4817.
15. T.Weimer, W.Wormsbächer, U.Kronthaler, et al. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost. 2008;99:659–667.
16. G.C.White2nd, A.Beebe, B.Nielsen. Recombinant factor IX. Thromb Haemost. 1997;78:261–265. Review.
17. K.Kurachi, E.W.Davie. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci USA. 1982;79:6461–6464.
18. M.J.Manco-Johnson, T.C.Abshire, A.D.Shapiro, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–544.•• The first randomized clinical trial (Joint Outcome Study) proving the advantages of prophylaxis versus on demand therapy in hemophilia.
19. A.Gringeri, B.Lundin, S.von Mackensen, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011;9:700–710.• The Italian study confirming the outcomes of American JOS.
20. P.W.Collins, S.Björkman, K.Fischer, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A:influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8:269–275.
21. I.E.Den Uijl, K.Fischer, J.G.Van Der Bom, et al. Analysis of low frequency bleeding data:the association of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011;17:41–44.
22. I.E.Den Uijl, E.P.Mauser Bunschoten, G.Roosendaal, et al. Clinical severity of haemophilia A:does the classification of the 1950s still stand?. Haemophilia. 2011;17:849–853.
23. G.J.Miller, D.J.Howarth, J.C.Attfield, et al. Haemostatic factors in human peripheral afferent lymph. Thromb Haemost. 2000;83:427–432.
24. S.Björkman, E.Berntorp. Pharmacokinetics of coagulation factors:clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001;40:815–832. Review.
25. D.M.Stern, M.Drillings, H.L.Nossel, et al. Binding of factors IX and IXa to cultured vascular endothelial cells. Proc Natl Acad Sci USA. 1983;80:4119–4123.
26. R.L.Heimark, S.M.Schwartz. Binding of coagulation factors IX and X to the endothelial cell surface. Biochem Biophys Res Commun. 1983;111:723–731.
27. E.Herzog, S.Harris, C.Henson, et al. Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats. Thromb Res. 2014;133:900–907.• This paper addressed very well the issue of tissue distribution of FIX.
28. C.Chaudhury, S.Mehnaz, J.M.Robinson, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med. 2003;197:315–322.
29. C.L.Anderson, C.Chaudhury, J.Kim, et al. Perspective–FcRn transports albumin:relevance to immunology and medicine. Trends Immunol. 2006;27:343–348.
30. J.Kim, C.L.Bronson, W.L.Hayton, et al. Albumin turnover:FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol. 2006;290:G352–G360.
31. E.Santagostino, C.Negrier, R.Klamroth, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 20 2012;120:2405–2411.•• This paper reports the outstanding PK data of crossover study of rFIX-FP versus pdFIX and rFIX concentrates.
32. U.Martinowitz, A.Lubetsky. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B. Thromb Res. 2013;131(Suppl 2):S11–S14.
33. E.Santagostino, U.Martinowitz, T.Lissitchkov, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B:results of a phase 3 trial. Blood. 2016;127:1761–1769.
34. J.S.Powell, K.J.Pasi, M.V.Ragni, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369:2313–2323.•• This paper reports the outcomes of crossover PK study of rFIXFc versus pdFIX and rFIX concentrates.
35. C.Negrier, K.Knobe, A.Tiede, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX:a first human dose trial in patients with hemophilia B. Blood. 2011;118:2695–2701.•• The paper shows the great PK advantages of N9-GP versus pdFIX and rFIX concentrates.
36. J.Oldenburg, B.Pezeshkpoor, A.Pavlova. Historical review on genetic analysis in hemophilia A. Semin Thromb Hemost. 2014 Nov;40(8):895–902.
37. D.Belvini, R.Salviato, P.Radossi, et al. Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica. 2005;90:635–642.
38. M.Morfini, A.Dragani, E.Paladino, et al. Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study. Haemophilia. 2016Mar;14. [Epub ahead of print] 10.1111/hae.12916.
39. J.M.Soucie, C.De Staercke, P.E.Monahan, et al. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. Transfusion. 2013;53:1217–1225.
40. C.P.Sharp, A.Lail, S.Donfield, et al. High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis. 2009;200:1119–1125.
41. S.Modrow, J.J.Wenzel, S.Schimanski, et al. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates. Vox Sang. 2011;100:351–358.
42. A.Bon, M.Morfini, A.Dini, et al. Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy:a case-report and literature review. Ital J Pediatr. 2015;41:12.
43. M.C.Ozelo. Surgery in patients with hemophilia:is thromboprophylaxis mandatory? Thromb Res. 2012;130(Suppl 1):S23–S26.
44. M.Ueno, I.Horikoshi, K.Takahashi, et al. Studies on oral administration of concentrated factor IX preparation. Yakugaku Zasshi. 1982;102:202–206.
45. N.Sakuragawa, K.Takahashi, I.Horikoshi, et al. Basic studies on oral and rectal administration of factor IX concentrate preparation. Nihon Ketsueki Gakkai Zasshi. 1983;46:190–196.
46. D.Verma, B.Moghimi, P.A.LoDuca, et al. Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc Natl Acad Sci USA. 2010;107:7101–7106.
47. A.J.Gerrard, D.E.Austen, G.G.Brownlee. Subcutaneous injection of factor IX for the treatment of haemophilia B. Br J Haematol. 1992;81:610–613.
48. D.Liles, C.N.Landen, D.M.Monroe, et al. Extravascular administration of factor IX:potential for replacement therapy of canine and human hemophilia B. Haemophilia. 1997;3:231.
49. S.I.Miekka, T.Jameson, M.Singh, et al. Novel delivery systems for coagulation proteins. Haemophilia. 1998;4:436–442.
50. K.E.Russell, E.H.Olsen, R.A.Raymer, et al. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. Blood. 2003;102:4393–4398.
51. A.R.Brooks, D.Sim, U.Gritzan, et al. Glycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacy. J Thromb Haemost. 2013;11:1699–1706.
52. J.Kim, W.L.Hayton, J.M.Robinson, et al. Kinetics of FcRn-mediated recycling of IgG and albumin in human:pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol. 2007;122:146–155.
53. M.Morfini, M.Lee, A.Messori. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/factor IX scientific and standardization committee of the international society on thrombosis and haemostasis. Thromb Haemost. 1991;66:384–386.
54. M.Lee, M.Morfini, S.Schulman, et al.; and the Factor VIII/Factor IX Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Posted in ISTH Website. 2001 Mar 21. Available from:www.isth.org/resource/group/d4a6f49a-f4ec-450f-9e0f-7be9f0c2ab2e/official_communications/fviiipharmaco.pdf?hhSearchTerms=%22morfini%22
55. A.D.Shapiro, M.V.Ragni, L.A.Valentino, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 2012;119:666–672.• This is the first paper reporting the PK outcomes of rFIXFc even though no cross-over study.
56. P.Collins, E.Chalmers, P.Chowdary, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice:guidance from UKHCDO. Haemophilia. 2016 Jul;22(4):487–498.